In this video interview, Sujay Jadhav, CEO of Verana Health, talks AI and its role in optimizing trial design.
In a recent video interview with Applied Clinical Trials, Sujay Jadhav, CEO of Verana Health, discussed potential advancements the clinical research industry could see in 2025. Jadhav highlighted how unstructured data like physician notes and imaging data can be leveraged to improve disease identification and progression tracking. He also talked synthetic control arms and how they can replace expensive non-treatment arms, enhancing trial efficiency.
ACT: How big of a part will artificial intelligence (AI) play in potential advancements around real-world evidence (RWE)/real-world data (RWD)?
Jadhav: Looking at how we leverage AI and real-world evidence/real-world data, it's going to play a substantial role, and it is starting to play a substantial role currently, right now, in unlocking the potential. There are multiple areas in which it is starting to unlock the potential. One that we're seeing and we're focusing on as well is predicting disease progression and assisting with early detection to support patient recruitment and retention, and so identifying suitable participants and helping reduce dropouts. The earlier you can do that, the more cost effective it can be in the overall clinical trial process. The other area where we're seeing and we're leveraging is identifying trends to inform data driven decisions across the product development life cycle, so helping improve the upfront process around how you optimize clinical trial design, and enabling adaptive trial design. Thematically, the more you can actually simulate what can happen with the particular clinical trial, and do that more upfront. That allows you to set up the actual trial from a logistical perspective more effectively and reduce costs and time as well. Also, as you go through that particular clinical trial leveraging AI to help support the adaptive trial design, if you need to actually change inclusion/exclusion criteria as you start to get results, leveraging AI to do that can be very, very helpful, as I said, and can help improve the overall effectiveness of the of the trial. The third area where we're seeing and leveraging AI quite a bit is enabling precision medicine, and that's by identifying subpopulations that are most likely to benefit from the treatment being investigated in a clinical trial, and ultimately helping drive and improve patient outcomes.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.